Study identifier:D4120C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Single-centre, Single-blind, Randomised, Placebo-controlled, Single-dose study to Assess the Safety, Tolerability and Pharmacokinetics after Single Ascending Intravenous Doses of AZD2927 in Healthy Male Subjects
Healthy
Phase 1
Yes
AZD2927, Placebo
Male
48
Interventional
18 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
In this early phase study, healthy male volunteers will be randomly assigned to one dose of either AZD2927 or placebo. The objective will be to assess the Safety,Tolerability and Pharmacokinetics of AZD2927.
Location
Location
UPPSALA, Sweden
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: AZD2927 Single dose of AZD2927 |
Placebo Comparator: 2 | Drug: Placebo Single dose of placebo |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.